These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 20832162

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Low-dose add-back therapy during postoperative GnRH agonist treatment.
    Tsai HW, Wang PH, Huang BS, Twu NF, Yen MS, Chen YJ.
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):55-9. PubMed ID: 26927249
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
    Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N.
    J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
    [Abstract] [Full Text] [Related]

  • 6. [GnRH agonist and add back therapy--indications, results and problems in the treatment of genital endometriosis].
    Mettler L.
    Zentralbl Gynakol; 2003 Oct; 125(7-8):267-75. PubMed ID: 14505262
    [Abstract] [Full Text] [Related]

  • 7. The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined with tibolone add-back therapy in endometriosis patients of reproductive age.
    Shin SY, Min JA, Yoon BK, Bae DS, Choi DS.
    Eur J Obstet Gynecol Reprod Biol; 2007 Jul; 133(1):90-4. PubMed ID: 16806656
    [Abstract] [Full Text] [Related]

  • 8. Add-back therapy in the treatment of endometriosis-associated pain.
    Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C, Sorrenti G.
    Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
    [Abstract] [Full Text] [Related]

  • 9. Gonadotropin-releasing hormone agonist with add-back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis.
    Lee DY, Lee JY, Seo JW, Yoon BK, Choi D.
    Arch Gynecol Obstet; 2016 Nov; 294(6):1257-1263. PubMed ID: 27549091
    [Abstract] [Full Text] [Related]

  • 10. Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo.
    Sesti F, Capozzolo T, Pietropolli A, Marziali M, Bollea MR, Piccione E.
    Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):72-7. PubMed ID: 19665279
    [Abstract] [Full Text] [Related]

  • 11. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
    Hornstein MD, Surrey ES, Weisberg GW, Casino LA.
    Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].
    Niu ZR, Yue XJ, Kong QY, Wang YF, Yao YQ.
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):338-43. PubMed ID: 24016475
    [Abstract] [Full Text] [Related]

  • 14. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
    Chwalisz K, Surrey E, Stanczyk FZ.
    Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
    [Abstract] [Full Text] [Related]

  • 15. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
    Sadler Gallagher J, Feldman HA, Stokes NA, Laufer MR, Hornstein MD, Gordon CM, DiVasta AD.
    J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The role of add-back therapy in the United States.
    Olive DL.
    Drugs Today (Barc); 2005 Jul; 41 Suppl A():23-6. PubMed ID: 16200222
    [Abstract] [Full Text] [Related]

  • 20. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
    Mitwally MF, Gotlieb L, Casper RF.
    Menopause; 2002 Jul; 9(4):236-41. PubMed ID: 12082359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.